Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (68)	9/27/2002 2:09:03 PM
From: tuck	Read Replies (1) \| Respond to of 566

>>Friday September 27, 1:32 pm ET WASHINGTON -(Dow Jones)- Rigel Pharmaceuticals Inc. (NasdaqNM:RIGL - News) Chairman and Chief Executive James Gower bought 76,000 shares of the company's common stock, according to a Form 4 filing with the Securities and Exchange Commission Friday. Gower purchased the stock Wednesday and Thursday at prices ranging from $1.54 a share to $1.65 a share. Following the transactions, Gower directly held 588, 142 shares of Rigel common stock, the filing said. Shares of Rigel traded recently at $1.50, down 3.9%. Based in South San Francisco, Rigel Pharmaceuticals develops drug candidates with its rapid drug target identification and validation technology.<< Cheers, Tuck